Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.21.1
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Balance attributable to Bio-Techne $ 1,381,192  
Balance attributable to Bio-Techne 1,539,453  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance attributable to Bio-Techne (13,253) $ (9,537)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (13) (6,413)
Reclassification from loss on derivatives to earnings or interest expense, net of taxes, attributable to Bio-Techne 5,503 [1] 1,614 [2]
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne (13) (6,413)
Balance attributable to Bio-Techne [3] (7,763) (14,336)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance attributable to Bio-Techne (83,946) (73,983)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 27,686 (15,138)
Reclassification from loss on derivatives to earnings or interest expense, net of taxes, attributable to Bio-Techne 0 [1] 0
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne 27,686 (15,138)
Balance attributable to Bio-Techne [3] (56,260) (89,121)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]    
Balance attributable to Bio-Techne (97,199) (83,521)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 27,673 (21,551)
Reclassification from loss on derivatives to earnings or interest expense, net of taxes, attributable to Bio-Techne 5,503 [1] 1,614 [2]
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne 27,673 (21,551)
Balance attributable to Bio-Techne [3] $ (64,023) $ (103,458)
[1] Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.
[2] The Company reclassified ($2,102) to interest expense and a related tax benefit tax of $488 during the nine months ended March 31, 2020.
[3] The Company had deferred tax benefits of $2,394 and $4,390 included in the accumulated other comprehensive income loss as of March 31, 2021 and March 31, 2020, respectively.